Skip to content

US · LMRI · MEDICAL - DEVICES

Lumexa Imaging Holdings, Inc. Common Stock (LMRI) intrinsic value and stock valuation

$14.26as of 2026-11-21 · Mkt cap 1.09B

Data updated · price as of 2026-11-21

Fairly valuedIC value is within 20% of the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Lumexa Imaging Holdings, Inc. Common Stock DCF and intrinsic value

InvestorsCraft values LMRI with the Chepakovich two-stage DCF model — currently rated fairly valued. How the model works · Run your own DCF prefilled from LMRI’s statements →

Lumexa Imaging Holdings, Inc. Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Devices Raleigh, NC 27609 lumexaimaging.com

How the business is doing

Fiscal 2023–2025, USD

Revenue
$1.02B
20232025
Net income
-$-47.1M
20232025
Free cash flow
-$-6.4M
20232025
Total equity
$586.1M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2023–2025, USD
202520242023
Revenue$1.02B$948.9M$935.9M
Operating income$26.7M$55.2M$22.5M
Net income-$-47.1M-$-94.1M-$-122.23M
EPSd-$-663.57K-$-995.03K-$-1.29M
Operating cash flow$17.1M$40.7M$37.5M
Capital expenditure-$-23.48M-$-27.77M-$-24.01M
Free cash flow-$-6.4M$13M$13.5M
Total assets$1.76B$1.71B$1.67B
Total debt$962.5M$1.31B$1.3B
Net debt$903.7M$1.28B$1.28B
Total equity$586.1M$161.7M$198.4M
Cash and short-term investments$58.8M$26.1M$20.2M
Income statement
202520242023
Revenue$1.02B$948.9M$935.9M
Cost of revenue$905.9M$852.6M$837M
Gross profit$117.2M$96.3M$99M
Research and development expenses$0.00$0.00$0.00
Selling, general and administrative expenses$90.5M$70.4M$55.2M
Other expenses$0.00-$-29.34M$21.4M
Operating expenses$90.5M$41M$76.5M
Cost and expenses$996.4M$893.6M$913.5M
Interest income$0.00$0.00$0.00
Interest expense$118.5M$136M$141.7M
Depreciation and amortization$55.4M$57.2M$72.1M
Ebitda$141.7M$114M$94.6M
Operating income$26.7M$55.2M$22.5M
Total other income/expenses, net-$-58.95M-$-134.44M-$-141.69M
Income before tax-$-32.22M-$-79.19M-$-119.25M
Income tax expense$14.9M$14.9M$2.98M
Net income-$-47.1M-$-94.1M-$-122.23M
Weighted average shares outstanding$71M$94.6M$94.6M
Weighted average diluted shares outstanding$71M$94.6M$94.6M
Balance sheet
202520242023
Cash and short-term investments$58.8M$26.1M$20.2M
Net receivables$150.9M$136M$130.3M
Inventory$0.00$0.00$0.00
Total current assets$227.3M$172.5M$166.8M
Property, plant and equipment, net$221.3M$201.9M$195.8M
Goodwill and intangible assets$848.9M$855.3M$865.9M
Long-term investments$423.2M$415.8M$422.5M
Total non-current assets$1.54B$1.5B$1.5B
Total assets$1.76B$1.71B$1.67B
Accounts payable$44.9M$29.9M$24.4M
Short-term debt$38.8M$35.3M$37.2M
Deferred revenue$0.00$0.00$0.00
Total current liabilities$179.2M$173.7M$161.1M
Long-term debt$923.7M$1.27B$1.27B
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$999.2M$1.34B$1.31B
Capital lease obligations$128.8M$108.2M$108.5M
Total liabilities$1.18B$1.51B$1.47B
Common stock$100K$745.6M$688.3M
Retained earnings-$-631.06M-$-583.96M-$-489.86M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity$586.1M$161.7M$198.4M
Total investments$423.2M$415.8M$422.5M
Total debt$962.5M$1.31B$1.3B
Net debt$903.7M$1.28B$1.28B
Cash flow statement
202520242023
Net income-$-47.1M-$-94.1M-$-122.23M
Depreciation and amortization$55.4M$57.2M$72.1M
Stock-based compensation$41.6M$56.7M$55.3M
Change in working capital-$-44.35M-$-2.6M-$-4.14M
Accounts receivable-$-14.01M-$-5.32M-$-15.3M
Inventory$0.00$0.00$0.00
Accounts payable$14.4M$2.95M$4.76M
Net cash provided by operating activities$17.1M$40.7M$37.5M
Investments in property, plant and equipment-$-23.48M-$-27.77M-$-24.01M
Acquisitions, net$2.64M$5.13M-$-5.65M
Net cash used for investing activities-$-20.96M-$-22.28M-$-29.66M
Common stock issued$427.8M$670K$2.25M
Common stock repurchased$0.00$0.00-$-120K
Dividends paid$0.00$0.00$0.00
Net cash used for financing activities$36.6M-$-12.5M-$-8.77M
Net change in cash$32.7M$5.95M-$-910K
Cash at end of period$58.8M$26.1M$20.2M
Operating cash flow$17.1M$40.7M$37.5M
Capital expenditure-$-23.48M-$-27.77M-$-24.01M
Free cash flow-$-6.4M$13M$13.5M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Lumexa Imaging Holdings, Inc. Common Stock

        Lumexa Imaging Holdings, Inc. manages and operates diagnostic imaging centers throughout the United States. These facilities deliver a comprehensive range of outpatient medical imaging solutions, encompassing advanced procedures like Magnetic Resonance Imaging (MRI), Computed Tomography (CT), and Positron Emission Tomography (PET) scans, in addition to standard diagnostic and screening services such as X-rays, ultrasounds, and mammography. The company was founded in 2018 and its primary base of operations is in Raleigh, North Carolina.

        CEO
        Caitlin Zulla
        Employees
        0
        Beta
        0.99

        Explore

        Frequently asked questions

        What is the intrinsic value of Lumexa Imaging Holdings, Inc. Common Stock (LMRI)?

        Lumexa Imaging Holdings, Inc. Common Stock (LMRI) is currently fairly valued based on the InvestorsCraft IC model — IC value is within 20% of the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is LMRI undervalued?

        LMRI trades at a price of $14.26 (Nov 21, 2026): fairly valued — IC value is within 20% of the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.